Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 27 Apr 2023
Residential and Outpatient Schizophrenia Patients' Sleep Health Varies.
Read Full NewsThe history of lobotomy shows the risks for limited evidence and oversight, while modern approaches emphasize targeted treatment, informed consent, and rigorous evaluation.
US radiologists vary substantially in their reading of low-dose CT lung cancer screens, highlighting a need for measures to help standardize interpretation.
Researchers compare first-line chemotherapy regimens in older patients with classical Hodgkin lymphoma to assess whether AVD is associated with better outcomes in routine care.
Researchers analyze individual patient data from five randomized phase 3 trials comparing PORT alone vs PORT plus hormone therapy in patients with recurrent prostate cancer.
A new real-world analysis helps clarify the most informative prognostic PSA benchmark in men with metastatic castration-sensitive prostate cancer.
Tissue-free ctDNA may be comparable to tumor-informed assays in detecting molecular residual disease.
1.
Tafasitamab Combo Boosts R-CHOP in Frontline DLBCL
2.
Recent research suggests that vitamin supplements may increase the risk of developing cancer.
3.
The way that miR-377 inhibits cells that cause prostate cancer.
4.
Chemicals in Sewage Sludge Fertilizer Pose Cancer Risk, EPA Says
5.
Durvalumab Wins FDA Approval in Limited-Stage SCLC
1.
New Hope for Rectal Cancer Patients: Breakthrough Drug Shows Promising Results
2.
Cancer Care Advances: Metformin, Digital Tools, and Artificial Renal Support
3.
CAR-T Cell Therapy for B-Cell Acute Lymphoblastic Leukemia: A Comprehensive Review
4.
Iron Deficiency Anemia: Modern Diagnostic Approaches and Personalized Treatment Strategies
5.
Reshaping the Battlefield Through Tumor Microenvironment Modulation for Cancer Therapy
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
1.
Efficient Management of First line ALK-rearranged NSCLC - Part III
2.
Targeting Oncologic Drivers with Dacomitinib: A New Approach to Lung Cancer Treatment
3.
Dissecting Molecular differences between EGFR Exon 19 deletion and Exon 21 L858R Mutations
4.
A Continuation to The Evolving Landscape of First-Line Treatment for Urothelial Carcinoma
5.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part III
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge